These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21497135)

  • 1. Prolyl cis/trans isomerase signalling pathways in cancer.
    Theuerkorn M; Fischer G; Schiene-Fischer C
    Curr Opin Pharmacol; 2011 Aug; 11(4):281-7. PubMed ID: 21497135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptidyl-prolyl isomerases: functionality and potential therapeutic targets in cardiovascular disease.
    Rostam MA; Piva TJ; Rezaei HB; Kamato D; Little PJ; Zheng W; Osman N
    Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):117-24. PubMed ID: 25377120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational perspective and evaluation of plausible catalytic mechanisms of peptidyl-prolyl cis-trans isomerases.
    Ladani ST; Souffrant MG; Barman A; Hamelberg D
    Biochim Biophys Acta; 2015 Oct; 1850(10):1994-2004. PubMed ID: 25585011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer.
    Stifani S
    Biomolecules; 2018 Oct; 8(4):. PubMed ID: 30314361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone.
    Hennig L; Christner C; Kipping M; Schelbert B; Rücknagel KP; Grabley S; Küllertz G; Fischer G
    Biochemistry; 1998 Apr; 37(17):5953-60. PubMed ID: 9558330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptidyl prolyl cis/trans-isomerases: comparative reactivities of cyclophilins, FK506-binding proteins, and parvulins with fluorinated oligopeptide and protein substrates.
    Golbik R; Yu C; Weyher-Stingl E; Huber R; Moroder L; Budisa N; Schiene-Fischer C
    Biochemistry; 2005 Dec; 44(49):16026-34. PubMed ID: 16331962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer.
    Finn G; Lu KP
    Curr Cancer Drug Targets; 2008 May; 8(3):223-9. PubMed ID: 18473735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases.
    Edlich F; Fischer G
    Handb Exp Pharmacol; 2006; (172):359-404. PubMed ID: 16610367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advances in the study of pin1 and its inhibitors].
    Zhang CJ; Zhang ZH; Xu BL; Wang YL
    Yao Xue Xue Bao; 2008 Jan; 43(1):9-17. PubMed ID: 18357725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolyl cis-trans isomerization as a molecular timer.
    Lu KP; Finn G; Lee TH; Nicholson LK
    Nat Chem Biol; 2007 Oct; 3(10):619-29. PubMed ID: 17876319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Trypanosoma cruzi PIN1 gene encodes a parvulin peptidyl-prolyl cis/trans isomerase able to replace the essential ESS1 in Saccharomyces cerevisiae.
    Erben ED; Daum S; Téllez-Iñón MT
    Mol Biochem Parasitol; 2007 Jun; 153(2):186-93. PubMed ID: 17418434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidomain Peptidyl Prolyl cis/trans Isomerases.
    Schiene-Fischer C
    Biochim Biophys Acta; 2015 Oct; 1850(10):2005-16. PubMed ID: 25445709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis.
    Rippmann JF; Hobbie S; Daiber C; Guilliard B; Bauer M; Birk J; Nar H; Garin-Chesa P; Rettig WJ; Schnapp A
    Cell Growth Differ; 2000 Jul; 11(7):409-16. PubMed ID: 10939594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual inhibitor against prolyl isomerase Pin1 and cyclophilin discovered by a novel real-time fluorescence detection method.
    Mori T; Hidaka M; Lin YC; Yoshizawa I; Okabe T; Egashira S; Kojima H; Nagano T; Koketsu M; Takamiya M; Uchida T
    Biochem Biophys Res Commun; 2011 Mar; 406(3):439-43. PubMed ID: 21333629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases.
    Perrucci GL; Gowran A; Zanobini M; Capogrossi MC; Pompilio G; Nigro P
    Cardiovasc Res; 2015 Jun; 106(3):353-64. PubMed ID: 25750190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation-specific prolyl isomerization: is there an underlying theme?
    Wulf G; Finn G; Suizu F; Lu KP
    Nat Cell Biol; 2005 May; 7(5):435-41. PubMed ID: 15867923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].
    Marsolier J; Weitzman JB
    Med Sci (Paris); 2014; 30(8-9):772-8. PubMed ID: 25174754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the catalytic mechanism of peptidyl prolyl cis/trans isomerases.
    Fanghänel J; Fischer G
    Front Biosci; 2004 Sep; 9():3453-78. PubMed ID: 15353370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Function of Pin1 in Vivo and Its Inhibitors for Preclinical Study: Early Development, Current Strategies, and Future Directions.
    He S; Li L; Jin R; Lu X
    J Med Chem; 2023 Jul; 66(14):9251-9277. PubMed ID: 37438908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition.
    Schutkowski M; Bernhardt A; Zhou XZ; Shen M; Reimer U; Rahfeld JU; Lu KP; Fischer G
    Biochemistry; 1998 Apr; 37(16):5566-75. PubMed ID: 9548941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.